2.96
Editas Medicine Inc Aktie (EDIT) Neueste Nachrichten
Editas Medicine Inc. Rebound Backed by Sentiment Shift2025 Price Action Summary & Consistent Income Trade Recommendations - sundaytimes.kr
Editas Medicine Inc. Pullback Analyzed — Is It Time to Exit2025 Buyback Activity & Growth Oriented Trade Recommendations - thegnnews.com
Editas Medicine Inc. Faces Significant Business Risks: Key Factors for Investors to Watch - TipRanks
Editas Medicine Reports Q2 2025 Progress and Financials - TipRanks
Editas Medicine’s SWOT analysis: gene editing stock faces challenges, opportunities - Investing.com
A Quick Look at Today's Ratings for Editas Medicine(EDIT.US), With a Forecast Between $3 to $6 - 富途牛牛
Editas Medicine Surges 34% on Q2 Momentum and Strategic Milestones – What’s Fueling the Biotech Rally? - AInvest
Can Editas Medicine Inc. Regain Momentum After BreakdownQuarterly Profit Review & Precise Buy Zone Identification - 선데이타임즈
Baird raises Editas Medicine stock price target to $6 on pipeline progress - Investing.com Nigeria
Editas Medicine (EDIT) Reports Q2 Loss, Tops Revenue Estimates - MSN
Editas: Q2 Earnings Snapshot - New Haven Register
Editas Medicine 2025 Q2 Earnings Narrows Losses Amid Revenue Surge - AInvest
Editas Medicine's Q2 Performance: Assessing Progress Amid Financial Challenges - AInvest
Editas Medicine Misses Expectations But Stays Focused On The Future - Finimize
Editas Medicine earnings missed by $0.23, revenue topped estimates - Investing.com South Africa
Editas Medicine Inc Q2 2025 Earnings: Revenue Soars to $3.6M, Beating Estimates; EPS Misses at -$0.63 - GuruFocus
Editas Medicine posts Q2 net loss of $53.2 mln - MarketScreener
Editas Medicine Q2 2025: On track to file IND by mid-2026, proof-of-concept by year-end. - AInvest
Editas Medicine Announces Second Quarter 2025 Results and Business Updates - GlobeNewswire
Editas Medicine Reports Q2 2025 Results, Advances Gene Editing Programs - AInvest
Editas Medicine narrows losses as Bristol Myers Squibb partnership hits key milestone - Stock Titan
Editas Medicine, Inc. (NASDAQ:EDIT) Shares Bought by XTX Topco Ltd - MarketBeat
Published on: 2025-08-09 06:19:25 - Newser
Quantitative breakdown of Editas Medicine Inc. recent moveInvestment Timeline and ROI Summary Report - Newser
Analysts Set Editas Medicine, Inc. (NASDAQ:EDIT) PT at $4.70 - MarketBeat
Editas Medicine, Inc. (NASDAQ:EDIT) EVP Linda Burkly Sells 5,121 Shares - MarketBeat
What makes Editas Medicine Inc. stock price move sharplyExit Strategy Guide With Risk Control Plan - Newser
Editas Medicine SVP Parison Amy Sells 679 Shares at $2.58/Share. - AInvest
Evaluating Editas Medicine Inc. with trendline analysisAI Stock Movement Forecast with Accuracy - Newser
How Interest Rate Changes Impact Editas Medicine Inc. Stock PerformanceAI Entry Timing Prediction for Swing Traders - Newser
Editas Medicine, Inc. (NASDAQ:EDIT) Shares Sold by Bank of New York Mellon Corp - Defense World
Can you recover from losses in Editas Medicine Inc.Free Early Breakout Entry Point Notifications - Newser
Editas Medicine EVP Sells Shares to Meet Tax Obligations - TradingView
Trendlines Converge — Decision Point for Editas Medicine Inc.Real Profit Trade Plan Suggestions Shared Widely - beatles.ru
Editas Medicine (EDIT) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Why is Editas Medicine Inc. stock attracting strong analyst attentionAccess powerful market insights for free - Jammu Links News
How strong is Editas Medicine Inc. company’s balance sheetConsistently superior profits - Jammu Links News
What are analysts’ price targets for Editas Medicine Inc. in the next 12 monthsUnlock powerful trading alerts for success - Jammu Links News
When is Editas Medicine Inc. stock expected to show significant growthGet alerts on top growth stocks daily - Jammu Links News
What institutional investors are buying Editas Medicine Inc. stockBuild wealth faster with disciplined trading - Jammu Links News
Should I hold or sell Editas Medicine Inc. stock in 2025Maximize your portfolio’s earning power - Jammu Links News
Is Editas Medicine Inc. a growth stock or a value stockHigh-profit stock alerts - Jammu Links News
Cwm LLC Has $55,000 Stake in Editas Medicine, Inc. (NASDAQ:EDIT) - Defense World
What is Editas Medicine Inc. company’s growth strategyTriple-digit profit margins - Jammu Links News
What are the technical indicators suggesting about Editas Medicine Inc.Invest smarter with actionable trading signals - Jammu Links News
Is Editas Medicine Inc. stock overvalued or undervaluedAchieve consistent double-digit growth rates - Jammu Links News
What catalysts could drive Editas Medicine Inc. stock higher in 2025High-yield trading alerts - Jammu Links News
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):